Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Cutting Edge: FcγRIII (CD16) and FcγRI (CD64) Are Responsible for Anti-Glycoprotein 75 Monoclonal Antibody TA99 Therapy for Experimental Metastatic B16 Melanoma

Cutting Edge: FcγRIII (CD16) and FcγRI (CD64) Are Responsible for Anti-Glycoprotein 75 Monoclonal... http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png The Journal of Immunology Unpaywall

Cutting Edge: FcγRIII (CD16) and FcγRI (CD64) Are Responsible for Anti-Glycoprotein 75 Monoclonal Antibody TA99 Therapy for Experimental Metastatic B16 Melanoma

Download PDF
Loading next page...
 
/lp/unpaywall/cutting-edge-fc-riii-cd16-and-fc-ri-cd64-are-responsible-for-anti-wxTCVFMPXi

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Unpaywall
ISSN
0022-1767
DOI
10.4049/jimmunol.1201511
Publisher site
See Article on Publisher Site

Abstract

Journal

The Journal of Immunology – Unpaywall

Published: Dec 15, 2012

There are no references for this article.